Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Isotechnika Pharma Inc IPHAF

Healthcare Biotechnology


GREY:IPHAF - Post by User

Isotechnika Pharma Inc > Is Lux in a bad spot?
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(6)
•••
Comment by teeveeon Jul 27, 2010 12:18pm
409 Views
Post# 17300190

RE: RE: Is Lux in a bad spot?

RE: RE: Is Lux in a bad spot?I doubt bridge financing is available unless from LUX. ISA's last loan was secured by the patents. Paladin owns the patents now. ISA has little if any assets to secure a loan with. The only way I see ISA obtaining bridge financing from LUX is if ISA's solvency threatens LUX's partnership on voclosporin.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities